These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34192864)

  • 21. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.
    Prisciandaro M; Antista M; Raimondi A; Corti F; Morano F; Centonze G; Sabella G; Mangogna A; Randon G; Pagani F; Prinzi N; Niger M; Corallo S; Castiglioni di Caronno E; Massafra M; Bartolomeo MD; de Braud F; Milione M; Pusceddu S
    Front Oncol; 2022; 12():780716. PubMed ID: 35186729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive significance of p53 and ATRX in neuroendocrine neoplasms of GIT and pancreas and their utility as an adjunct to accurate diagnosis-An eight-year retrospective study.
    Ail DA; Paulose RR
    Indian J Gastroenterol; 2024 Oct; ():. PubMed ID: 39352684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors.
    Donadio MD; Brito ÂB; Riechelmann RP
    Ther Adv Med Oncol; 2023; 15():17588359231156218. PubMed ID: 36950274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
    Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
    Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report.
    Ito M; Hirano Y; Isii T; Kondo H; Wang L; Asari M; Obara N; Yamaguchi S
    Surg Case Rep; 2020 Jun; 6(1):130. PubMed ID: 32533349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
    Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
    Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.
    Graf A; Welch J; Bansal R; Mandl A; Parekh VI; Cochran C; Levy E; Nilubol N; Patel D; Sadowski S; Jha S; Agarwal SK; Millo C; Blau JE; Simonds WF; Weinstein LS; Del Rivero J
    J Endocr Soc; 2022 Oct; 6(10):bvac122. PubMed ID: 36111275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 36. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G3 GEP NENs category: are basic and clinical investigations well integrated?
    Milione M; Fazio N
    Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
    Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
    Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.